Skip to main content

Table 2 Prognostic factors for recurrence-free survival identified by univariate and multivariate analyses (n = 139)

From: Impact of low skeletal muscle mass index and perioperative blood transfusion on the prognosis for HCC following curative resection

     Univariate Multivariate
Variables n (%) 3-year survival 5-year survival P-value HR 95% CI P-value
Male sex 110 (79%) 45.8% 41.2% 0.180    
Female sex 29 (21%) 56.6% 40.4%     
Age (years)
  ≤ 80 109 (78%) 24.9% 24.9% 0.084    
  > 80 30 (22%) 52.4% 45.2%     
BMI (kg/m2)
  > 25 34 (25%) 48.0% 48.0% 0.699    
  ≤ 25 105 (75%) 48.3% 39.3%     
ALBI
 grade III 30 (22%) 49.5% 44.6% 0.708    
  < grade III 109 (78%) 47.7% 40.1%     
HBV
 (+) 27 (19%) 63.2% 47.7% 0.236    
 (−) 112 (81%) 44.1% 37.7%     
HCV
 (+) 70 (50%) 40.8% 38.6% 0.163    
 (−) 69 (50%) 56.4% 44.2%     
DM
 (+) 29 (21%) 57.5% 43.6% 0.674    
 (−) 110 (79%) 45.2% 39.9%     
NLR
  ≥ 4 13 (9%) 19.4% 19.4% 0.279    
  < 4 126 (91%) 49.9% 42.5%     
PLT (×104/μL)
 normal (13–35) 97 (70%) 50.4% 42.4% 0.595    
 abnormal 42 (30%) 44.1% 39.2%     
Hb (g/dL)
 normal (13.5–15.8) 95 (68%) 50.5% 41.6% 0.795    
 abnormal 44 (32%) 44.3% 40.9%     
PT (%)
 normal (70–130) 125 (90%) 50.5% 42.5% 0.125    
 abnormal 14 (10%) 28.8% 28.8%     
AST (U/L)
 normal (13–33) 71 (51%) 45.6% 33.9% 0.888    
 abnormal 68 (49%) 51.1% 48.1%     
ALT (U/L)
 normal (8–42) 100 (72%) 48.8% 41.0% 0.770    
 abnormal 39 (28%) 46.8% 40.9%     
CHE (g/dL)
 normal (229–521) 77 (55%) 53.8% 44.9% 0.251    
 abnormal 62 (45%) 41.7% 36.4%     
Alb (g/dL)
 normal (4.0–5.0) 115 (83%) 48.5% 39.8% 0.878    
 abnormal 24 (17%) 46.7% 46.7%     
T-chol (mg/dL)
 normal (128–219) 118 (85%) 49.4% 43.0% 0.907    
 abnormal 20 (14%) 42.1% 31.6%     
PIVKA-II (mAU/mL)
normal (< 40) 62 (45%) 61.0% 51.0% 0.048 1.321 0.778–2.240 0.320
abnormal 77 (55%) 37.7% 33.0%     
AFP (ng/mL)
normal (> 10) 68 (49%) 58.8% 48.9% 0.036 1.612 0.960–2.707 0.071
abnormal 68 (49%) 38.7% 33.5%     
Tumor number
solitary 113 (81%) 51.8% 44.5% 0.025 1.810 1.025–3.197 0.041
multiple 26 (19%) 31.4% 18.8%     
Tumor size
 3 cm < 71 (51%) 49.5% 43.4% 0.938    
  ≤ 3 cm 54 (39%) 52.6% 42.7%     
Poor differentiation 20 (14%) 42.1% 28.1% 0.337    
Others (well, moderately) 119 (86%) 49.3% 43.6%     
IM
(+) 19 (14%) 5.6% 5.6% < 0.001 4.115 2.255–7.510 < 0.001
(−) 120 (86%) 56.1% 47.5%     
Vp
(+) 26 (19%) 28.4% 28.4% 0.016 1.490 0.824–2.695 0.187
(−) 113 (81%) 52.8% 43.5%     
Low SMI 86 (62%) 46.1% 39.8% 0.335    
High SMI 53 (38%) 51.9% 43.9%     
Blood transfusion
(+) 22 (16%) 24.6% 24.6% 0.008 2.288 1.244–4.207 0.008
(−) 117 (84%) 52.4% 44.4%     
  1. Variables in bold are statistically significant (P < 0.05). Abbreviations: BMI, Body mass index; ALBI, albumin-bilirubin; HBV, hepatitis type B; HCV, hepatitis type C; DM, diabetes mellitus; NLR, neutrophil-to-lymphocyte ratio; PLT, platelets; Hb, hemoglobin; PT, prothrombin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CHE, cholinesterase; Alb, albumin; T-chol, total-cholesterol; PIVKAII, protein induced by vitamin K absence or antagonist-II; AFP, α-fetoprotein; IM, intrahepatic metastasis; Vp, portal vain invasion; SMI, skeletal muscle mass index